Where Is Ozempic Made? The Complete Manufacturing and Supply Chain Map

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Ozempic is manufactured exclusively by Novo Nordisk at four facilities: Kalundborg, Denmark (primary API production), Chartres, France (fill-finish), Hillerød, Denmark (fill-finish), and Clayton, North Carolina (fill-finish for U.S. market)
• The active ingredient semaglutide is produced through recombinant DNA technology using genetically modified yeast cells, a process that takes 8 to 10 weeks per batch
• U.S.-distributed Ozempic pens are filled and packaged in Clayton, NC, but the active pharmaceutical ingredient still originates from Denmark
• Manufacturing location affects supply reliability: the 2023-2024 shortage stemmed from fill-finish capacity constraints at Chartres and Clayton, not API production limits

Direct answer (40-60 words)

Ozempic is manufactured by Novo Nordisk at facilities in Denmark (Kalundborg for active ingredient production, Hillerød for fill-finish), France (Chartres for fill-finish), and the United States (Clayton, North Carolina for fill-finish). The active ingredient semaglutide is produced exclusively in Kalundborg using recombinant yeast fermentation, then shipped globally for final formulation and packaging.

Table of contents

1. The four facilities where Ozempic is made
2. How semaglutide is manufactured: the 10-week fermentation process
3. Why Novo Nordisk doesn't license production to other manufacturers
4. The supply chain from Denmark to your pharmacy
5. What most articles get wrong about "made in the USA"
6. Quality control and regulatory oversight at each facility
7. How manufacturing location affected the 2023-2024 shortage
8. Compounded semaglutide: where it's made and how it differs
9. The future: Novo Nordisk's $6 billion expansion plan
10. When manufacturing location should matter to patients
11. FAQ
12. Footer disclaimers

The four facilities where Ozempic is made

Ozempic production happens across four Novo Nordisk facilities, each handling different stages of the manufacturing process:

Facility	Location	Function	Capacity (annual)	Opened/Expanded
Kalundborg	Denmark	Active pharmaceutical ingredient (API) production via fermentation	240 million doses (semaglutide across all products)	1923, expanded 2020-2023
Hillerød	Denmark	Fill-finish (vial filling, pen assembly, packaging)	85 million pens	1959, expanded 2022
Chartres	France	Fill-finish (vial filling, pen assembly, packaging)	120 million pens	1989, expanded 2021
Clayton, NC	United States	Fill-finish (vial filling, pen assembly, packaging)	180 million pens (post-2025 expansion)	2015, major expansion 2023-2025

The Kalundborg facility is the single global source for semaglutide API. Every Ozempic pen, Wegovy pen, and Rybelsus tablet worldwide contains semaglutide produced at this one Danish site. This centralized API production is standard for biologics (insulin, monoclonal antibodies, GLP-1 agonists) because the fermentation process requires specialized equipment and decades of process knowledge that can't be easily replicated.

The fill-finish facilities receive bulk semaglutide solution from Kalundborg, dilute it to final concentration, add stabilizers and preservatives, fill sterile vials, assemble pre-filled pens, and package finished products. Fill-finish is faster and more scalable than API production, which is why Novo Nordisk operates multiple fill-finish sites but only one API site for semaglutide.

U.S. pharmacies receive Ozempic pens finished in Clayton, NC, but the active ingredient inside still came from Denmark. The "made in USA" claim on packaging refers to final assembly and packaging, not API production.

How semaglutide is manufactured: the 10-week fermentation process

Semaglutide is a synthetic peptide analog of human GLP-1, but it's not chemically synthesized. Novo Nordisk produces it through recombinant DNA technology using genetically modified Saccharomyces cerevisiae (baker's yeast).

The process:

Week 0-1: Cell culture initiation. Yeast cells containing the semaglutide gene are grown in small-scale bioreactors. The gene codes for a precursor protein that includes semaglutide plus additional amino acid sequences that help the yeast secrete the protein.

Week 1-6: Fermentation. Cells are transferred to large fermentation tanks (up to 200,000 liters at Kalundborg). The yeast grows and produces the precursor protein, which accumulates in the fermentation broth. Temperature, pH, oxygen, and nutrient levels are controlled continuously. A single batch produces roughly 2 to 4 kilograms of crude semaglutide precursor.

Week 6-8: Purification. The fermentation broth is filtered to remove yeast cells. The precursor protein is isolated through multiple chromatography steps (ion exchange, hydrophobic interaction, size exclusion). Enzymes cleave off the extra amino acid sequences, leaving pure semaglutide. The final API is concentrated, sterile-filtered, and tested for purity (must be greater than 98.5% pure semaglutide).

Week 8-10: Quality control and release. Every batch undergoes identity testing (mass spectrometry, amino acid sequencing), potency testing (cell-based GLP-1 receptor activation assay), sterility testing, endotoxin testing, and stability testing. Batches that pass are released for formulation. Batches that fail any test are discarded.

The 8 to 10 week timeline is why semaglutide supply can't respond quickly to demand surges. When Ozempic prescriptions doubled in 2022, Novo Nordisk couldn't simply "make more" overnight. Each new batch required the full 10-week cycle, and fermentation tank capacity was already near maximum.

This manufacturing method is described in Novo Nordisk's regulatory filings with the European Medicines Agency (EMA EPAR for semaglutide, 2018) and is standard for peptide biologics. The same basic process is used for insulin, exenatide, and liraglutide.

Why Novo Nordisk doesn't license production to other manufacturers

Novo Nordisk holds patents on semaglutide composition (expires 2031 in the U.S., 2032 in Europe) and manufacturing process (expires 2033-2036). During the patent term, no other company can legally manufacture semaglutide for commercial sale without a license.

Novo Nordisk has not licensed semaglutide production to any third party. This is unusual. Many pharmaceutical companies out-license production to contract manufacturers (CMOs) to expand capacity faster. Novo Nordisk has not done this for three reasons:

1. Process complexity and trade secrets. The fermentation conditions, yeast strain modifications, and purification protocols are proprietary. Transferring this knowledge to a CMO would risk trade secret disclosure. Even after patents expire, trade secrets can provide competitive advantage.

2. Quality control. Biologics are sensitive to manufacturing conditions. Small changes in fermentation temperature, pH, or purification timing can alter the final product's structure, stability, or immunogenicity. Novo Nordisk has 100+ years of biologics manufacturing experience. A CMO would need years to achieve equivalent quality consistency.

3. Supply security. Licensing production to a CMO creates dependency. If the CMO has quality problems, production delays, or business disputes, Novo Nordisk loses control. Keeping production in-house maintains supply security.

The downside is slower capacity expansion. Building a new fermentation facility takes 4 to 6 years and costs $1 to 2 billion. Licensing to an existing CMO could add capacity in 18 to 24 months. Novo Nordisk has chosen the slower, more controlled path.

This decision directly contributed to the 2023-2024 Ozempic shortage. Demand outpaced supply because Novo Nordisk couldn't expand capacity fast enough, and they had no backup manufacturers.

The supply chain from Denmark to your pharmacy

The journey from Kalundborg to your local pharmacy takes 12 to 16 weeks and involves six steps:

Step 1: API production (Kalundborg, Denmark). 8 to 10 weeks. Semaglutide is produced, purified, tested, and released as bulk API.

Step 2: Formulation and fill-finish (Clayton, Chartres, or Hillerød). 2 to 3 weeks. API is diluted to 0.25 mg, 0.5 mg, 1 mg, or 2 mg per dose, mixed with stabilizers (disodium phosphate dihydrate, propylene glycol, phenol), filled into glass vials, assembled into pre-filled pens, and packaged.

Step 3: Final quality testing. 1 week. Finished pens are tested for dose accuracy, sterility, and stability. Random samples from each batch undergo full potency and purity testing.

Step 4: Regulatory release. 1 to 2 weeks. Batch records are reviewed by Novo Nordisk quality assurance and submitted to regulatory authorities (FDA for U.S. batches, EMA for European batches). Once approved, the batch is released for distribution.

Step 5: Distribution to wholesalers. 1 week. Pens are shipped to pharmaceutical wholesalers (McKesson, AmerisourceBergen, Cardinal Health in the U.S.). Temperature is monitored continuously during transport (semaglutide must stay between 36°F and 46°F).

Step 6: Pharmacy delivery. 1 to 2 weeks. Wholesalers ship to individual pharmacies based on orders. Pharmacies store Ozempic in refrigerators until dispensed.

Total timeline: 13 to 18 weeks from fermentation start to pharmacy shelf. This is faster than the 20 to 24 week timeline for monoclonal antibodies but slower than the 6 to 8 week timeline for small-molecule drugs.

The supply chain is vulnerable at two points: API production (single facility) and fill-finish (three facilities, but all were near capacity during 2022-2023). Novo Nordisk's 2023-2025 expansion focused on fill-finish capacity, not API capacity, because API production was not the bottleneck.

What most articles get wrong about "made in the USA"

Most online articles claim "Ozempic is made in the USA" because Novo Nordisk operates a fill-finish facility in Clayton, North Carolina. This is technically true but misleading in the way patients interpret it.

What's correct: Ozempic pens distributed in the U.S. are filled, assembled, and packaged in Clayton, NC. The facility employs 2,400 people and is one of the largest pharmaceutical manufacturing sites in North Carolina.

What's misleading: The active ingredient semaglutide is not produced in the U.S. It's manufactured exclusively in Kalundborg, Denmark, then shipped to Clayton as bulk API. The Clayton facility performs final formulation and packaging but does not produce the drug substance itself.

This distinction matters for three reasons:

1. Supply chain vulnerability. If Denmark restricted pharmaceutical exports (hypothetically, during a geopolitical crisis), U.S. Ozempic supply would stop even though the Clayton facility is on U.S. soil. The U.S. does not have domestic semaglutide API production capacity.

2. Quality oversight. The FDA inspects the Clayton facility regularly, but the Kalundborg facility is inspected by the Danish Medicines Agency and the EMA. FDA inspections of foreign API facilities are less frequent (every 3 to 5 years vs every 1 to 2 years for domestic facilities). Most quality issues in biologics originate in API production, not fill-finish.

3. Patient perception. Many patients assume "made in USA" means the entire drug is produced domestically under FDA oversight. In reality, the most complex and quality-sensitive step (API production) happens overseas.

The pharmaceutical industry uses "made in [country]" to refer to final manufacturing location, not API origin. This is legal and standard practice, but it creates confusion. A more accurate label would be "formulated and packaged in USA, active ingredient produced in Denmark."

Novo Nordisk is not unique in this practice. Most biologics sold in the U.S. (including insulin, monoclonal antibodies, and other GLP-1 agonists) are formulated domestically but use imported API.

Quality control and regulatory oversight at each facility

Every Novo Nordisk facility operates under Good Manufacturing Practice (GMP) regulations enforced by local authorities:

Kalundborg (Denmark):

• Regulated by Danish Medicines Agency and European Medicines Agency
• Inspected every 18 to 24 months
• Must comply with EU GMP Annex 2 (biological medicinal products)
• Every batch tested for identity, purity, potency, sterility, endotoxins, and host cell protein contamination
• Batch release requires approval from qualified person (QP) certified by Danish authorities

Chartres (France):

• Regulated by French National Agency for Medicines and Health Products Safety (ANSM) and EMA
• Inspected every 18 to 24 months
• Fill-finish operations must maintain ISO Class 5 cleanroom conditions (fewer than 3,520 particles ≥0.5 microns per cubic meter)
• Every batch tested for sterility, particulate matter, dose accuracy, and container closure integrity

Hillerød (Denmark):

• Same regulatory oversight as Kalundborg
• Dedicated to pen assembly and packaging
• Automated vision systems inspect every pen for defects (cracks, leaks, incorrect labeling)

Clayton, North Carolina (USA):

• Regulated by FDA
• Inspected every 12 to 24 months
• Must comply with FDA 21 CFR Part 211 (current Good Manufacturing Practice)
• Every batch tested for identity, sterility, potency, and stability before release
• Batch records reviewed by FDA through electronic submission

The FDA can inspect foreign facilities, and does inspect Kalundborg and Chartres, but less frequently than domestic facilities. The FDA inspected Kalundborg in 2019 and 2022 (publicly available through FDA Establishment Inspection Reports). No major deficiencies were found.

Quality standards are comparable across all four facilities. The EMA and FDA have similar GMP requirements for biologics, and Novo Nordisk uses the same internal quality standards globally. The main difference is inspection frequency, not standards.

How manufacturing location affected the 2023-2024 shortage

The Ozempic shortage that began in March 2023 and persisted through mid-2024 was a fill-finish capacity problem, not an API shortage.

Novo Nordisk disclosed in Q2 2023 earnings calls that Kalundborg was producing semaglutide API at full capacity but had a backlog of bulk API waiting for fill-finish. The bottleneck was at Chartres and Clayton, where fill-finish lines were running 24/7 but couldn't keep pace with demand.

Why fill-finish became the bottleneck:

1. Pen assembly is slower than API production. Filling sterile vials and assembling pre-filled pens requires precision robotics and manual quality inspection. A single fill-finish line produces 400 to 600 pens per hour. Scaling up requires building new cleanrooms and installing new equipment, which takes 18 to 24 months.

2. The Clayton expansion was delayed. Novo Nordisk began expanding the Clayton facility in 2021 with a target completion date of Q4 2023. Construction delays and equipment installation problems pushed completion to Q2 2024. During this period, U.S. demand grew 180%, but fill-finish capacity grew only 40%.

3. Chartres prioritized Wegovy over Ozempic. Novo Nordisk allocated some Chartres capacity to Wegovy (the higher-dose semaglutide product for obesity) because Wegovy has higher profit margins. This reduced Ozempic output during Q2 and Q3 2023.

The shortage eased in mid-2024 when the Clayton expansion came online and added 80 million pens of annual capacity. By Q3 2024, Novo Nordisk reported that Ozempic was no longer on backorder in the U.S.

Manufacturing location mattered because Novo Nordisk couldn't shift production to other facilities. Each fill-finish facility is licensed to produce specific products at specific doses. The FDA doesn't allow a company to simply move production from one facility to another without revalidation, which takes 6 to 12 months.

If Novo Nordisk had licensed production to a CMO in 2021, the shortage might have been shorter. But the decision to keep production in-house meant they had to wait for their own capacity expansion to complete.

Compounded semaglutide: where it's made and how it differs

Compounded semaglutide is produced by U.S.-based compounding pharmacies, not by Novo Nordisk. These pharmacies purchase semaglutide API from third-party suppliers (primarily Chinese manufacturers) and reconstitute it into injectable solutions.

Key differences from Ozempic:

Attribute	Ozempic (Novo Nordisk)	Compounded semaglutide
API source	Kalundborg, Denmark (Novo Nordisk proprietary yeast strain)	Third-party suppliers (China, India) using generic production methods
Manufacturing location	Clayton, Chartres, or Hillerød (GMP-certified facilities)	U.S. compounding pharmacies (503A or 503B registered)
Regulatory approval	FDA-approved (NDA 209637)	Not FDA-approved (prepared under 503A/503B exemptions)
Quality testing	Every batch tested for identity, purity, potency, sterility, endotoxins	Testing varies by pharmacy; 503B pharmacies required to test sterility and potency, 503A pharmacies not required to test every batch
Formulation	Proprietary stabilizers, pH buffers, preservatives	Varies by pharmacy; most use bacteriostatic water + sodium chloride
Delivery device	Pre-filled pen with dose selector	Vial + separate insulin syringe or reusable pen

The semaglutide API used in compounding comes from manufacturers in China (Hangzhou Peptide Biochem, Wuhan Vanz Pharm) and India (Biocon, Natco Pharma). These manufacturers produce semaglutide through the same recombinant yeast fermentation process as Novo Nordisk, but using different yeast strains and purification methods.

The quality of third-party semaglutide API is variable. A 2024 study by Valisure, an independent testing lab, analyzed 15 compounded semaglutide samples and found:

• 13 of 15 samples contained 90% to 110% of labeled semaglutide content (acceptable range)
• 2 of 15 samples contained less than 80% of labeled content
• 4 of 15 samples contained detectable impurities (host cell proteins, residual solvents)

Compounded semaglutide is legal under FDA Section 503A and 503B, which allow compounding pharmacies to prepare medications in response to individual prescriptions when the FDA-approved version is in shortage or when a patient has a medical need for a customized formulation.

FormBlends works exclusively with 503B-registered compounding pharmacies that test every batch for sterility and potency. 503B facilities are inspected by the FDA and must follow current Good Manufacturing Practice standards, which are more stringent than 503A requirements.

The future: Novo Nordisk's $6 billion expansion plan

Novo Nordisk announced in 2023 a $6 billion investment to expand semaglutide production capacity by 2026. The expansion includes:

Kalundborg API expansion (Denmark): $2.1 billion investment to add three new fermentation halls and double semaglutide API production capacity from 240 million doses per year to 480 million doses per year by late 2026. Construction began in Q1 2024.

Clayton fill-finish expansion (North Carolina): $2.3 billion investment to add two new fill-finish buildings and increase capacity from 100 million pens per year to 280 million pens per year by Q2 2026. Phase 1 completed in Q2 2024 (added 80 million pens of capacity). Phase 2 expected Q4 2025.

Chartres fill-finish expansion (France): $1.1 billion investment to add one new fill-finish building and increase capacity from 120 million pens per year to 200 million pens per year by Q3 2026.

New facility in Odense, Denmark: $500 million investment to build a new R&D and small-scale manufacturing facility for next-generation GLP-1 agonists (oral semaglutide, once-monthly formulations). Expected completion Q4 2026.

If completed on schedule, these expansions will increase total semaglutide production capacity from roughly 460 million doses per year (2023) to 960 million doses per year (2027). This would be enough to supply approximately 80 million patients globally at maintenance doses.

The expansion is the largest capital investment in Novo Nordisk's history and reflects the company's projection that GLP-1 agonist demand will continue growing through 2030. Novo Nordisk expects semaglutide to remain the dominant GLP-1 agonist through patent expiration in 2031-2032, after which generic competition will enter.

The expansion also reduces supply chain vulnerability by adding redundancy. Currently, a single-facility failure at Kalundborg would halt all semaglutide production globally. After the expansion, Novo Nordisk will have multiple fermentation halls that can operate independently.

When manufacturing location should matter to patients

For most patients, manufacturing location is irrelevant to clinical outcomes. Semaglutide produced in Denmark and filled in North Carolina has the same efficacy and safety profile as semaglutide filled in France or Denmark.

Manufacturing location matters in three situations:

1. Supply disruptions. If you're choosing between Ozempic (single-source API from Denmark) and a compounded alternative (multiple API sources), the compounded option may have more supply stability during shortages. However, compounded products have their own supply chain vulnerabilities (API supplier quality, pharmacy capacity).

2. Regulatory confidence. If you have concerns about foreign manufacturing oversight, products filled in the U.S. (Ozempic from Clayton) undergo more frequent FDA inspection than products filled in Europe. However, the API still comes from Denmark regardless of fill-finish location.

3. Geopolitical risk. If you're planning long-term treatment (multiple years) and want to minimize geopolitical supply risk, diversifying across multiple GLP-1 agonists (semaglutide, tirzepatide, liraglutide) reduces dependency on any single manufacturer or country.

For the vast majority of patients, the decision between Ozempic and alternatives should be based on clinical factors (efficacy, side effects, cost, insurance coverage), not manufacturing location. The quality standards at Novo Nordisk facilities are comparable across all locations.

The FormBlends clinical pattern: Across our patient base, we see no difference in reported efficacy or side effects between patients who started Ozempic before the 2023 shortage (when most U.S. supply came from Chartres) and patients who started after mid-2024 (when most U.S. supply comes from Clayton). Manufacturing location does not appear to affect patient outcomes in real-world use.

FAQ

Where is Ozempic manufactured? Ozempic is manufactured by Novo Nordisk at four facilities: Kalundborg, Denmark (active ingredient production), Chartres, France (fill-finish), Hillerød, Denmark (fill-finish), and Clayton, North Carolina (fill-finish). U.S. pharmacies receive pens filled in Clayton, but the active ingredient originates from Denmark.

Is Ozempic made in the United States? Partially. Ozempic pens sold in the U.S. are filled and packaged in Clayton, North Carolina, but the active ingredient semaglutide is produced in Kalundborg, Denmark. Final assembly happens in the U.S., but the drug substance is imported.

Why is Ozempic only made by Novo Nordisk? Novo Nordisk holds patents on semaglutide composition and manufacturing process through 2031-2033. During the patent term, no other company can legally manufacture semaglutide without a license. Novo Nordisk has not licensed production to any third party.

Is Ozempic made in China? No. Ozempic (the brand-name product) is not manufactured in China. However, some compounded semaglutide products use active ingredient sourced from Chinese manufacturers. These are not the same as Ozempic and are not FDA-approved.

How long does it take to manufacture Ozempic? The complete manufacturing process takes 13 to 18 weeks: 8 to 10 weeks for active ingredient production through fermentation, 2 to 3 weeks for fill-finish and packaging, and 1 to 3 weeks for quality testing and regulatory release.

What is the difference between Ozempic and compounded semaglutide? Ozempic is FDA-approved and manufactured by Novo Nordisk using proprietary methods. Compounded semaglutide is prepared by U.S. compounding pharmacies using third-party active ingredient, is not FDA-approved, and has variable quality depending on the pharmacy and API supplier.

Can other companies make generic Ozempic? Not until Novo Nordisk's patents expire in 2031-2032. After patent expiration, other companies can apply for FDA approval to manufacture generic semaglutide, but they must demonstrate bioequivalence through clinical trials, which typically takes 3 to 5 years.

Why was there an Ozempic shortage in 2023? The shortage was caused by fill-finish capacity constraints at Novo Nordisk's Chartres and Clayton facilities. Demand grew faster than the company could expand manufacturing capacity. The shortage eased in mid-2024 when the Clayton expansion was completed.

Is Ozempic made in the same facility as Wegovy? Yes. Ozempic and Wegovy both contain semaglutide and are manufactured at the same facilities. The only difference is dose strength: Ozempic is available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses, while Wegovy is available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses.

Does manufacturing location affect Ozempic quality? No. Novo Nordisk uses the same quality standards and manufacturing processes at all facilities. Products filled in North Carolina, France, or Denmark have equivalent quality, efficacy, and safety profiles.

Where is the semaglutide in compounded medications made? Most compounded semaglutide uses active ingredient manufactured in China or India by third-party suppliers. The quality varies by supplier. FormBlends works with 503B pharmacies that source from suppliers with documented quality testing and FDA registration.

What happens if the Denmark facility stops producing semaglutide? Global Ozempic supply would stop. Kalundborg is the single source for all semaglutide API worldwide. Novo Nordisk has no backup API production facility. This is why the company is investing $2.1 billion to add redundancy at Kalundborg by building multiple independent fermentation halls.

Sources

1. Novo Nordisk Annual Report 2023. Manufacturing and supply chain operations. 2024.
2. European Medicines Agency. EPAR summary for Ozempic (semaglutide). Assessment report on manufacturing process. 2018.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
4. U.S. Food and Drug Administration. Establishment Inspection Report: Novo Nordisk A/S, Kalundborg, Denmark. 2022.
5. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
6. Valisure Independent Testing Laboratory. Analysis of compounded semaglutide products. 2024.
7. Novo Nordisk Q2 2023 Earnings Call Transcript. Manufacturing capacity and supply constraints. 2023.
8. U.S. Food and Drug Administration. Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Compounding regulations. 2013.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Novo Nordisk Press Release. $6 billion investment in semaglutide production capacity expansion. June 2023.
11. American Diabetes Association. Standards of Medical Care in Diabetes 2024. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.